Table 3.

Risk for generalized and focal distant adverse events after BoNT-A treatment.

Variable	Odds Ratio	p-Value	95% CI	Relative Risk	95% CI
Gender: F/M	2.564	0.029	1.101–5.973	1.899	1.060–3.400
Total dose (U): ≥400/<400	2.171	0.095	0.875–5.390	1.651	0.945–2.885
Body weight (kg): ≥45/<45	1.662	0.285	0.654–4.223	1.432	0.725–2.831
Number of treated body parts (n): ≥6/<6	1.214	0.667	0.501–2.940	1.141	0.631–2.063
GMFCS level: IV–V/I–III	1.080	0.866	0.442–2.636	1.054	0.568–1.955
Age (y): ≥10/<10	0.975	0.952	0.424–2.242	0.982	0.554–1.741
Dose (U/kg): ≥10/<10	0.809	0.618	0.352–1.859	0.866	0.492–1.523

F: female; M: male; CI: confidence interval; GMFCS: Gross Motor Function Classification System.